Drugs & Therapy Perspectives

, Volume 14, Issue 12, pp 8–12 | Cite as

What can be Done to Stop the Global Threat of Tuberculosis?

New Drugs and Disease Management


Tuberculosis Isoniazid Healthcare Worker Moxonidine Bacille Calmette Guerin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Choi C. Management of tuberculosis: special considerations. Dis Manage Health Outcomes 1998 Oct; 4 (4): 205–16CrossRefGoogle Scholar
  2. 2.
    Sawert H. The re-emergence of tuberculosis and its economic implications. Pharmacoeconomics 1996 May; 9 (5): 379–81Google Scholar
  3. 3.
    Greener M. Tuberculosis: out of sanitoriums and into complacency. Pharmacoecon Outcomes News 1998 Jan 9: 194: 3–4Google Scholar
  4. 4.
    Hopewell PC. Tuberculosis and human immunodeficiency virus infection. Semin Respir Infect 1989; 4: 111–22PubMedGoogle Scholar
  5. 5.
    Brewer TF, Wilson ME, Nardell EA. BCG immunisation: review of past experience, current use, and future prospects. Curr Clin Topics Inf Dis 1995; 15: 253–70Google Scholar
  6. 6.
    Whyte K, Zhanel G. Role of the BCG vaccine for prevention of tuberculosis in Canada. Can J Hosp Pharm 1997 Oct; 50 (5): 233–6Google Scholar
  7. 7.
    Lowrie DB, Silva CL, Tascon RE. Progress towards a new tuberculosis vaccine. BioDrugs 1998 Sep; 10 (3): 201–13PubMedCrossRefGoogle Scholar
  8. 8.
    Centers for Disease Control and Prevention. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: ajoint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunisation Practices. MMWR Morbid Mortal Wkly Rep 1996 Apr; 45 (RR-4): 1–18Google Scholar
  9. 9.
    Robertson JM, Burtt DS, Edmonds KL, et al. Delayed tuberculin reactivity in persons of indochinese origin: implications for preventive therapy. Ann Intern Med 1996 May; 124 (9): 779–84PubMedGoogle Scholar
  10. 10.
    Centers for Disease Control and Prevention. Essential components of a tuberculosis prevention and control program; and screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morbid Mortal Wkly Rep 1995 Sep; 44 (44–11): 1–34Google Scholar
  11. 11.
    Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections. Treatment of tuberculosis and tuberculosis infection in adults and children. Clin Infect Dis 1995 Jul; 21: 9–27CrossRefGoogle Scholar
  12. 12.
    Mohle-Boetani JC, Miller B, Halpern M, et al. School-based screening for tuberculosis infection: a cost-benefit analysis. JAMA 1995 Aug; 274 (8): 613–9PubMedCrossRefGoogle Scholar
  13. 13.
    Snider Jr DE, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986 Mar; 255 (12): 1579–83PubMedCrossRefGoogle Scholar
  14. 14.
    Salpeter SR, Sanders GD, Salpeter EE, et al. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997 Dec; 127 (12): 1051–61PubMedGoogle Scholar
  15. 15.
    World TB Day discussions. Scrip 1999 Mar 26; 2423: 14Google Scholar
  16. 16.
    Castelo A, Mathiasi PA, Iunes R, et al. Cost effectiveness of antituberculosis interventions. Pharmacoeconomics 1995 Nov; 8 (5): 385–99PubMedCrossRefGoogle Scholar
  17. 17.
    Barnum HN. Cost savings from alternative treatments for tuberculosis. Soc Sci Med 1986; 23: 847–50PubMedCrossRefGoogle Scholar
  18. 18.
    Condos R, Schluger NW. Cytokine-based approaches to the treatment of multidrug-resistant tuberculosis. BioDrugs 1999 Mar; 11 (3): 165–73PubMedCrossRefGoogle Scholar

Copyright information

© Adis International LTD 1999

Personalised recommendations